EIF3B correlates with advanced disease stages and poor prognosis, and it promotes proliferation and inhibits apoptosis in non-small cell lung cancer

Tian, Yuan; Zhao, Kunpeng; Yuan, Luer; Li, Jialing; Feng, Shuangbing; Feng, Yufeng; Fang, Zhongqi; Li, Hui; Deng, Ruoyu

doi:10.3233/cbm-181628

Cited by 32 publications

(40 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All IHC procedures were performed as described in a previous study [13]. Finally, the expression of katanin P60 in tissue specimen was assessed by IHC score, which was obtained using a semi-quantitative scoring method as previously described [14]. The total IHC score was ranging from 0 to 12.…”

Section: Ihc Stainingmentioning

confidence: 99%

Katanin P60: a potential biomarker for lymph node metastasis and prognosis for non-small cell lung cancer

2020

View full text Add to dashboard Cite

Background: This study aimed to assess the correlation of katanin P60 expression with clinical characteristics and survival profiles of surgical non-small cell lung cancer (NSCLC) patients. Methods: Two hundred and sixty-five primary NSCLC patients treated by surgical resection were retrospectively viewed. The expression of katanin P60 in the tumor specimen was detected by the immunohistochemical (IHC) staining assay. Preoperative clinical data were collected from patients' medical records, and survival data were extracted from follow-up records. Results: There were 127 (47.9%) and 138 (52.1%) patients with katanin P60-low expression and-high expression, respectively; in addition, patients presenting katanin P60-high+,-high++, and-high+++ expression were 62 (23.4%), 63 (23.8%), and 13 (4.9%), respectively. Katanin P60 expression was correlated with lymph node (LYN) metastasis and advanced TNM stage but not pathological grade, tumor size, carcinoembryonic antigen (CEA) level or other non-tumor features in NSCLC patients. Regarding survival profiles, disease-free survival (DFS) and overall survival (OS) were both the lowest in katanin P60-high+++ expression patients, followed with katanin P60-high++ patients, katanin P60-high+ patients, and the highest in katanin P60-low expression patients. Further analysis illustrated that katanin P60-high expression was an independent predictive factor for unfavorable DFS and OS in NSCLC patients. Conclusions: Katanin P60 presents potential as a biomarker for lymph node metastasis and prognosis in NSCLC patients.

show abstract

Section: Ihc Stainingmentioning

confidence: 99%

Katanin P60: a potential biomarker for lymph node metastasis and prognosis for non-small cell lung cancer

2020

View full text Add to dashboard Cite

show abstract

“…Several studies have demonstrated that overexpressed eIF3b could promote the progression of malignant cancers such as glioblastoma cells [14],colon cancer [15], osteosarcoma [16] and lung cancer [17]. In addition, we have revealed the tumor-promoting function of eIF3b in ESCC in previous study [6], however, the underlying molecular mechanism remains elusive.…”

Section: Discussionmentioning

confidence: 81%

TEX9 and eIF3b functionally synergize to promote the progression of esophageal squamous cell carcinoma

Zhang

Liu

et al. 2019

BMC Cancer

View full text Add to dashboard Cite

Background Esophageal squamous cell carcinoma (ESCC) is one of the most frequent malignant digestive tumors around the world. We previously demonstrated that eIF3b could promote the progression of ESCC. The exact mechanisms underlying these effects remained unknown. Methods Quantitative proteomics was applied to detect the potential targets of Eukaryotic translation initiation factor 3 subunit b (eIF3b). RT-qPCR and Western blot were performed to detect the expression of targeted gene and pathway related genes. RNA-immunoprecipitation was applied to verify the binding of eIF3b with targeted gene. Moreover, CCK-8 assay, colony-formation assay, transwell assay, flow cytometry for cell apoptosis and tumor xenograft assay were performed to analyze the regulation of the targeted gene on the bio-function of ESCC cells. Results Quantitative proteomics data showed that Testis-expressed protein 9 (TEX9) expression was positively associated with eIF3b expression. RT-qPCR and Western blot results confirmed the quantitative proteomics data and demonstrated that TEX9 expression was positively correlated with TNM stage in ESCC. Furtherly, RNA-immunoprecipitation confirmed that eIF3b binding to TEX9 mRNA. The bio-function related assay demonstrated that TEX9 and eIF3b functionally synergized to promote the proliferation and migration, and inhibited the apoptosis of ESCC cells. In the analysis of mechanism, we revealed that TEX9 and eIF3b promoted the progression of ESCC through the activation of AKT signaling pathway. Conclusions The synergized promoting role of TEX9 and eIF3b in the progression of ESCC may provide a novel mechanism for exploring viable therapeutic strategies for ESCC. Electronic supplementary material The online version of this article (10.1186/s12885-019-6071-9) contains supplementary material, which is available to authorized users.

show abstract

“…Furthermore, high expression of EIF3B was associated with poor relapse-free survival in the subgroups of females, older patients, R0, G2 and stage III. However, Tian et al (11) reported that upregulation of EIF3B was associated with tumor depth, TNM stage and lymph node metastasis in patients with esophageal squamous cell carcinoma. However, the results of the present study indicated that EIF3B was related to histological grade and survival status.…”

Section: Discussionmentioning

confidence: 99%

“…In the present study, it was observed that upregulation of EIF3B was associated with poor overall/relapse-free survival of patients with liver cancer. In addition, patients with high EIF3B expression in clear cell renal cell carcinoma, esophageal squamous cell carcinoma and non-small cell lung cancer had a shorter survival time (6,7,11). In order to further explore the association between EIF3B and clinical characteristics of patients with liver cancer, a subgroup analysis was performed.…”

Section: Discussionmentioning

confidence: 99%

“…It is the rate-limiting step of protein synthesis and participates in numerous processes that are deregulated in cancer cells, including DNA repair and proliferation, cell cycle and apoptosis (5). EIF 3 subunit B (EIF3B) is an important member of the family of EIFs and has been observed to be overexpressed in numerous cancer types, including clear cell renal cell carcinoma (6), esophageal squamous cell carcinoma (7), glioblastoma (8), ovarian cancer (9), osteosarcoma (10) and lung cancer (11), and has an important role in the progression and prognosis of several cancer types (12)(13)(14). In addition, Golob-Schwarzl et al (15) reported that EIF3B was upregulated in hepatitis C virus (HCV)-associated hepatocellular carcinoma (HCC).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of eukaryotic translation initiation factor 3 subunit B in liver cancer and its prognostic significance

et al. 2020

View full text Add to dashboard Cite

Liver cancer is one of the major malignancies with the worst prognosis among all solid tumor types. It is therefore ponderable to explore prognostic biomarkers and therapeutic targets for liver cancer. Eukaryotic translation initiation factor 3 subunit B (EIF3B) is closely linked to the transcription initiation of cancer-associated genes. In the present study, EIF3B was indicated to be a potential prognostic biomarker of liver cancer. The mRNA expression level of EIF3B in liver cancer was assessed by analyzing the Cancer Genome Atlas dataset. χ 2 and Fisher's exact tests were used to assess the association of EIF3B expression with clinical parameters. Receiver-operating characteristic curve analysis was used for evaluating the diagnostic value of EIF3B. Overall and relapse-free survival were assessed using Kaplan-Meier curves to determine the association between EIF3B expression and survival. Univariate and multivariate Cox regression analysis were performed to identify the factors affecting overall/relapse-free survival. Gene set enrichment analysis (GSEA) was used to identify signaling pathways associated with EIF3B in liver cancer. It was revealed that EIF3B was highly expressed in liver cancer tissues and it had a promising diagnostic ability. Furthermore, the survival analysis indicated that patients with high EIF3B expression generally had shorter overall as well as relapse-free survival. Univariate and multivariate Cox analysis suggested that high EIF3B mRNA expression may serve as an independent biomarker for the prognostication of patients with liver cancer. GSEA suggested that MYC-V1 (HALLMARK_MYC_TARGETS_V1 geneset; P=0.009), MYC-V2 (HALLMARK_MYC_TARGETS_V2 geneset; P=0.004) and DNA repair pathways (HALLMARK_ DNA_REPAIR geneset; P<0.001) were differentially enriched in high EIF3B expression and low EIF3B expression groups. In conclusion, high EIF3B expression was indicated to be an independent prognostic biomarker for patients with liver cancer.

show abstract

EIF3B correlates with advanced disease stages and poor prognosis, and it promotes proliferation and inhibits apoptosis in non-small cell lung cancer

Abstract: EIF3B overexpression correlates with advanced disease conditions and poor prognosis, and it promotes cells proliferation while inhibits apoptosis in NSCLC.

Cited by 32 publications

References 21 publications

Katanin P60: a potential biomarker for lymph node metastasis and prognosis for non-small cell lung cancer

Katanin P60: a potential biomarker for lymph node metastasis and prognosis for non-small cell lung cancer

TEX9 and eIF3b functionally synergize to promote the progression of esophageal squamous cell carcinoma

Expression of eukaryotic translation initiation factor 3 subunit B in liver cancer and its prognostic significance

Contact Info

Product

Resources

About